| Code | CSB-RA704410MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is designed as a research-grade biosimilar to Oregovomab, targeting MUC16 (also known as CA125), a high molecular weight transmembrane mucin glycoprotein. MUC16 is extensively expressed on the surface of ovarian cancer cells and serves as a well-established tumor marker, playing critical roles in cell adhesion, immune evasion, and metastatic progression. The protein's aberrant overexpression and shedding into serum make it a valuable biomarker for monitoring ovarian cancer progression and treatment response. Elevated MUC16 levels are also associated with other malignancies including pancreatic, breast, and lung cancers.
Oregovomab is a murine monoclonal antibody that recognizes a specific epitope on the MUC16 antigen and has been investigated in clinical trials for ovarian cancer immunotherapy. This biosimilar antibody provides researchers with a reliable tool for investigating MUC16 biology, tumor-associated antigen expression, and immune responses in cancer models. It supports studies in oncology research, biomarker validation, and the development of diagnostic and therapeutic strategies targeting MUC16-expressing malignancies.
There are currently no reviews for this product.